Insights

Early-stage Growth NeuExcell Therapeutics is rapidly expanding its R&D efforts in neurodegenerative gene therapy, presenting an opportunity to engage with a company at a critical build phase where scalable research tools, collaboration platforms, and external R&D support services could accelerate progress.

Clinical Progress First-in-human study of NXL-004 for recurrent malignant glioma is being presented at ASCO 2026, signaling near-term clinical milestones and the potential need for CRO partnerships, clinical data management, imaging, and regulatory affairs services tailored to neuro-oncology.

Strategic Partnerships Past collaboration with Spark Therapeutics indicates openness to partnerships with established gene therapy players, suggesting receptivity to licensing discussions, co-development arrangements, and technology integration opportunities.

Funding & Validation Recent Series Pre-A+ financing and a reported revenue range position the company as an investment-backed, growing biotech with potential needs for scale-up services, grant and non-dilutive funding advisory, and pilot manufacturing support.

Global Impact Aimed at transforming outcomes for neurodegenerative diseases worldwide, NeuExcell presents a market-facing opportunity for patient access programs, outcomes data collaborations, and health economics partnering to demonstrate value and reimbursement potential.

Similar companies to NeuExcell Therapeutics

NeuExcell Therapeutics Tech Stack

NeuExcell Therapeutics uses 8 technology products and services including Sucuri, WordPress, Microsoft 365, and more. Explore NeuExcell Therapeutics's tech stack below.

  • Content Delivery Network
  • Content Management System
  • Font Awesome
    Font Scripts
  • Google Fonts API
    Font Scripts
  • Twemoji
    Font Scripts
  • jQuery
    Javascript Libraries
  • HTTP/3
    Web & Portal Technology

NeuExcell Therapeutics's Email Address Formats

NeuExcell Therapeutics uses at least 4 email formats:
NeuExcell Therapeutics Email FormatsExamplePercentage
FirstLast@neuexcell.comJohnDoe@neuexcell.com
63%
FirstLa@neuexcell.comJohnDo@neuexcell.com
23%
FLast@neuexcell.comJDoe@neuexcell.com
8%
FirLast@neuexcell.comJohDoe@neuexcell.com
6%

Frequently Asked Questions

What is NeuExcell Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
NeuExcell Therapeutics's official website is neuexcell.com and has social profiles on LinkedIn.

How much revenue does NeuExcell Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, NeuExcell Therapeutics's annual revenue is estimated to be $1M - $10M.

What is NeuExcell Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
NeuExcell Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does NeuExcell Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, NeuExcell Therapeutics has approximately 4 employees across 2 continents, including North America and Asia. Key team members include Chief Business And Strategy Officer: L. G., Vice President , Head Of Cmc And Tech Ops: K. Y. and Founder: G. C. Explore NeuExcell Therapeutics's employee directory with LeadIQ.

What industry does NeuExcell Therapeutics belong to?

Minus sign iconPlus sign icon
NeuExcell Therapeutics operates in the Biotechnology Research industry.

What technology does NeuExcell Therapeutics use?

Minus sign iconPlus sign icon
NeuExcell Therapeutics's tech stack includes Sucuri, WordPress, Microsoft 365, Font Awesome, Google Fonts API, Twemoji, jQuery and HTTP/3.

What is NeuExcell Therapeutics's email format?

Minus sign iconPlus sign icon
NeuExcell Therapeutics's email format typically follows the pattern of FirstLast@neuexcell.com. Find more NeuExcell Therapeutics email formats with LeadIQ.

How much funding has NeuExcell Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, NeuExcell Therapeutics has raised $25M in funding. The last funding round occurred on May 04, 2023.

When was NeuExcell Therapeutics founded?

Minus sign iconPlus sign icon
NeuExcell Therapeutics was founded in 2016.
NeuExcell Therapeutics logo

NeuExcell Therapeutics

Biotechnology ResearchPennsylvania, United States2-10 Employees

NeuExcell Therapeutics is a biotechnology research company focused on gene therapy approaches for neurodegenerative diseases. The organization aims to regenerate neurons in the brain with the goal of improving outcomes for patients facing serious neurological conditions. Its stated disease areas include stroke, Huntington's disease, ALS, and traumatic brain injury. It is based in King of Prussia, Pennsylvania, and described as a small team in the biotech sector.

The company positions itself within the biotechnology field as pursuing strategies to restore damaged neural tissue through gene therapy. In May 2026, NeuExcell announced that the first-in-human study of NXL-004 for recurrent malignant glioma will be presented at the ASCO 2026 meeting.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
2-10

Section iconFunding & Financials

  • $25M

    NeuExcell Therapeutics has raised a total of $25M of funding over 2 rounds. Their latest funding round was raised on May 04, 2023 as a Seed.

  • $1M - $10M

    NeuExcell Therapeutics's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.